Company Information

  

Address: 305 COLLEGE ROAD EAST  
City: PRINCETON, 
State: NJ 
Zip Code: 08540 
Telephone: 732 545 1590 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Advaxis, Inc. ("Advaxis" or the "Company") is a late-stage biotechnology Company focused on the discovery, development and commercialization of proprietary Lm Technology antigen delivery products based on a platform technology that utilizes live attenuated Listeria monocytogenes ("Lm") bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy by accessing and directing antigen presenting cells to stimulate anti-tumor T cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the Tumor Microenvironment ("TME") to enable the T cells to eliminate tumors. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
There's no share overview data.

Key Financial Ratios and Statistics

FYE: 10/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.26Total Liab/Total Assets0.42
Net Inc/Total Assets-1.00Total Liab/Inv Cap0.54
Net Inc/Inv Cap-1.28Total Liab/Comm Equity0.11
Pretax Inc/Net Sales-8.13Interest Coverage RatioNA
Net Inc/Net Sales-7.77Curr Debt/EquityNA
Cash Flow/Net Sales-6.39LTD/EquityNA
SG&A/NetSales3.21Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover3.44Quick Ratio3.89
Inventory TurnoverNACurrent Ratio3.89
Inventory Day SalesNANet Rec/Curr Assets0.05
Net Sales/Work Cap0.20Inv/Curr AssetsNA
Net Sales/PP&E1.69  

Income Statement (Millions)

  4/30/2018 1/31/2018 10/31/2017 7/31/2017
Total Revenues(Net Sales) 1.75 2.06 1.76 3.05
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 4.47 5.53 5.49 18.07
Operating Income -13.55 -20.55 -27.87 -32.81
Interest Exp NA NA NA NA
Pretax Income -13.41 -20.44 -27.71 -32.63
Other Income 0.15 0.11 0.16 0.19
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -13.41 -20.49 -23.26 -32.63

Balance Sheet (Millions)

Assets 4/30/2018 1/31/2018 10/31/2017 7/31/2017
Cash & Short Term Investments 58.84 59.35 70.89 89.41
Receivables - Total 0.00 0.00 4.45 1.73
Inventories - Total NA NA NA NA
Total Current Assets 65.48 63.99 81.24 97.88
Net Property, Plant & Equipment 7.75 7.92 7.11 7.34
Total Assets 79.17 77.44 93.64 110.72
Liabilities        
Accounts Payable 11.65 14.38 13.82 9.14
Debt in Current Liabilities NA NA NA 0.04
Total Current Liabilities 18.86 21.60 20.86 21.29
Long-Term Debt NA NA NA 0.29
Total Liabilities 33.71 38.17 39.38 36.36
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.05 0.04 0.04 0.04
Retained Earnings -335.04 -321.63 -301.14 -277.88
Treasury Stock NA NA 0.00 0.00
Total Stockholders' Equity 45.46 39.27 54.26 74.36
Total Liabilities and Stockholders' Equity 79.17 77.44 93.64 110.72

Cash Flow Summary (Millions)

Categories 4/30/2018 1/31/2018 10/31/2017 7/31/2017
Net Cash Provided by Operating Activities -18.14 -12.65 -18.39 -24.85
Net Cash Provided by Investing Activities 22.72 12.04 27.13 9.43
Net Cash Provided by Financing Activities 18.37 2.65 0.15 0.41

Annual Summary Data (Millions)

Year Sales Net Income EPS
10/20130.00-19.99--
10/20141.00-16.53--
10/20150.00-47.03--
10/20163.99-73.56--
10/201712.03-93.44--
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/187145--




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.